"RaRaMa" The Convergent Frequency-Based Cancer Therapeutics: A Comprehensive Framework for Multi-Modal Resonance Targeting
Year: 2025
Type: article
Abstract: **Abstract** Cancer treatment faces persistent challenges of selectivity, resistance, and systemic toxicity. Recent convergence of validated research in 2024-2025 across multiple frequency-based therapeutic modalities provides unprecedented opportunities for comprehensive theoretical framework development. This synthesis integrates FDA-approved histotripsy for liver cancer treatment, Nature Chemistry-published molecular jackhammers achieving 99% cancer cell eradication in laboratory studies, terahertz therapy demonstrating 10-70% DNA demethylation rates in preclinical studies, and gap junction modulation research from leading institutions. The framework establishes mathematical foundations through quantum mechanical vibrations, Peyrard-Bishop DNA models validated for 10¹²-10¹³ Hz breathing dynamics, beat frequency generation, and Lorentzian resonance targeting. Theoretical frequency-target correlations using the RaRaMa framework demonstrate notable precision: calculated sulforaphane molecular resonance (68.6 THz) showing 2.4% variance with CD133 cancer stem cell markers (70.3 THz), calculated berberine targeting (46.5 THz) matching KRAS G12 oncogene frequencies (46.9 THz) within 0.8% difference, suggesting potential for physics-based therapeutic targeting methodologies. Preclinical evidence spans multiple cancer types with translation potential: liver cancer (histotripsy treating patients), melanoma (molecular jackhammers in laboratory validation), brain cancer (terahertz penetration addressing access challenges), and metastatic disease (multi-modal targeting approaches). The convergence suggests movement toward physical targeting mechanisms that may complement existing chemical therapies. This theoretical synthesis documents validated technologies from Rice University, California Institute of Technology, University of Michigan, MD Anderson Cancer Center, RIKEN Institute, and international research institutions, published in Nature Chemistry, Scientific Reports, Applied Physics Letters, and IEEE conferences. The framework identifies clinical research directions while establishing mathematical foundations for frequency-based cancer therapeutics based on molecular resonance frequencies and validated enhancement mechanisms. **Keywords:** Terahertz therapy, molecular jackhammers, oncotripsy, histotripsy, gap junction intercellular communication, Peyrard-Bishop DNA dynamics, RaRaMa framework, cancer frequency targeting, precision medicine, multi-modal therapeutics
Author: Hansley, Dustin
Language: English
Subfield: Biomedical Engineering
Field: Engineering
Domain: Physical Sciences
Open Access status: green
OpenAlex ID: W7081998398
FWCI:
Cites:
Cited by:
Related to: